Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bermekimab in Moderate to Severe Hidradenitis Suppurativa
NCT04988308Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of bermekimab in hidradenitis suppurativa (HS) (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Hidradenitis Suppurativa Clinical Response-50 at 16 weeks. Started Oct 2021; status: terminated.
02
Drugs
bermekimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04988308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988308.